Effectiveness of CAR-T Treatment Toward the Potential Risk of Second Malignancies

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 May 17

PMID 38756776

Authors

Massimo Martino

Gaetana Porto

Giorgia Policastro

Caterina Alati

Barbara Loteta

Maria Caterina Mico

Clizia Argiro

Maria Altomonte

Tiziana Moscato

Demetrio Labate

Vincenzo Dattola

Carmelo Massimiliano Rao

Francesca Cogliandro

Filippo Antonio Canale

Virginia Naso

Gianfranco Filippelli

Antonino Iaria

Martina Pitea

Affiliations

Soon will be listed here.

References

Snowden J, Sanchez-Ortega I, Corbacioglu S, Basak G, Chabannon C, de la Camara R . Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022; 57(8):1217-1239. PMC: 9119216. DOI: 10.1038/s41409-022-01691-w. View

Ahmed B, Zafar M, Qadir M . Review: Oncogenic Insertional Mutagenesis as a Consequence of Retroviral Gene Therapy for X-Linked Severe Combined Immunodeficiency Disease. Crit Rev Eukaryot Gene Expr. 2020; 29(6):511-520. DOI: 10.1615/CritRevEukaryotGeneExpr.2019026820. View

Martin T, Usmani S, Berdeja J, Agha M, Cohen A, Hari P . Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2022; 41(6):1265-1274. PMC: 9937098. DOI: 10.1200/JCO.22.00842. View

Schwarzwaelder K, Howe S, Schmidt M, Brugman M, Deichmann A, Glimm H . Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest. 2007; 117(8):2241-9. PMC: 1934556. DOI: 10.1172/JCI31661. View

Locke F, Ghobadi A, Jacobson C, Miklos D, Lekakis L, Oluwole O . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2018; 20(1):31-42. PMC: 6733402. DOI: 10.1016/S1470-2045(18)30864-7. View

Baum C . Insertional mutagenesis in gene therapy and stem cell biology. Curr Opin Hematol. 2007; 14(4):337-42. DOI: 10.1097/MOH.0b013e3281900f01. View

Testa U, DAlo F, Pelosi E, Castelli G, Leone G . CAR-T Cell Therapy for Follicular Lymphomas. Mediterr J Hematol Infect Dis. 2024; 16(1):e2024012. PMC: 10786124. DOI: 10.4084/MJHID.2024.012. View

Nowakowski G, Blum K, Kahl B, Friedberg J, Baizer L, Little R . Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. J Natl Cancer Inst. 2016; 108(12). PMC: 6080361. DOI: 10.1093/jnci/djw257. View

Schubert M, Schmitt M, Wang L, Ramos C, Jordan K, Muller-Tidow C . Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2020; 32(1):34-48. DOI: 10.1016/j.annonc.2020.10.478. View

10.

Sehgal A, Hoda D, Riedell P, Ghosh N, Hamadani M, Hildebrandt G . Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022; 23(8):1066-1077. DOI: 10.1016/S1470-2045(22)00339-4. View

11.

Meadows A, Friedman D, Neglia J, Mertens A, Donaldson S, Stovall M . Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009; 27(14):2356-62. PMC: 2738645. DOI: 10.1200/JCO.2008.21.1920. View

12.

Martino M, Canale F, Naso V, Porto G, Gerace D, Allegra A . Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?. Int J Mol Sci. 2023; 24(2). PMC: 9861434. DOI: 10.3390/ijms24021045. View

13.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

14.

Crump M, Neelapu S, Farooq U, Van den Neste E, Kuruvilla J, Westin J . Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808. PMC: 5649550. DOI: 10.1182/blood-2017-03-769620. View

15.

Levine B, Pasquini M, Connolly J, Porter D, Gustafson M, Boelens J . Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024; 30(2):338-341. PMC: 11688691. DOI: 10.1038/s41591-023-02767-w. View

16.

Martino M, Canale F, Alati C, Vincelli I, Moscato T, Porto G . CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. Cancers (Basel). 2021; 13(11). PMC: 8197914. DOI: 10.3390/cancers13112639. View

17.

Martino M, Paviglianiti A . An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. Expert Opin Biol Ther. 2021; 21(8):1025-1034. DOI: 10.1080/14712598.2021.1872540. View

18.

Astrakhan A, Sather B, Ryu B, Khim S, Singh S, Humblet-Baron S . Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. Blood. 2012; 119(19):4395-407. PMC: 3362358. DOI: 10.1182/blood-2011-03-340711. View

19.

Tukenova M, Diallo I, Hawkins M, Guibout C, Quiniou E, Pacquement H . Long-term mortality from second malignant neoplasms in 5-year survivors of solid childhood tumors: temporal pattern of risk according to type of treatment. Cancer Epidemiol Biomarkers Prev. 2010; 19(3):707-15. DOI: 10.1158/1055-9965.EPI-09-1156. View

20.

Demoor-Goldschmidt C, De Vathaire F . Review of risk factors of secondary cancers among cancer survivors. Br J Radiol. 2018; 92(1093):20180390. PMC: 6435077. DOI: 10.1259/bjr.20180390. View